Godavari Biorefineries Limited has informed the Exchange regarding Board meeting held on May 24, 2025.
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Biorefineries' board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditor Verma Mehta & Associates issuing an unmodified (clean) opinion. Consolidated FY25 revenue from operations rose ~10.9% to Rs 1,87,025 lakhs (vs Rs 1,68,666 lakhs in FY24), driven by Sugar and Bio-based Chemicals segments. However, the company slipped into a consolidated net loss of Rs 2,311 lakhs in FY25, compared to a small profit of Rs 123 lakhs in FY24, largely due to a one-time deferred tax expense of Rs 2,449 lakhs triggered by the Finance Act 2024. Operating profit before interest fell to Rs 7,025 lakhs from Rs 8,801 lakhs, indicating margin pressure. The company raised Rs 32,500 lakhs via an IPO in October 2024, which was primarily used to repay debt (Rs 22,000 lakhs) and general corporate purposes, helping cut total borrowings. Standalone operating cash flow turned negative at Rs (133) lakhs vs Rs 19,637 lakhs in FY24. Tushar Shridharani & Associates LLP was appointed as Secretarial Auditor for five years, subject to shareholder approval.
Shareholders will see a FY25 net loss and sharply weaker cash generation, though the loss is largely driven by a one-time tax adjustment and revenue still grew double-digits. The IPO-led debt reduction improves the balance sheet, but margin compression and weak cash flows are concerns that may temper near-term sentiment.